Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Deutsches Arzteblatt International
|
August 28, 2019
The Systemic Treatment of Melanoma
Patrick Terheyden, Angela Krackhardt, Thomas Eigentler
Deutsche Medizinische Wochenschrift (1946)
|
July 14, 2018
[Immuno-Oncology: A Brief Overview]
Sebastian Kobold, Angela Krackhardt, Hans Schlösser, et al.
Melanoma Research
|
March 3, 2023
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography
Cornelius Berberich, Mona Mustafa, Yize Zhuwu, et al.
Molecular Therapy Oncolytics
|
January 22, 2019
Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
Michael Karl Melzer, Lisa Zeitlinger, Sabine Mall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Lisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Plos One
|
October 1, 2019
Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy
Benjamin Faist, Fabian Schlott, Christian Stemberger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 26, 2026
SH2D1A/SAP Reflects Immune Activation in Melanoma and Is a Superior Predictive Biomarker of Immune Checkpoint Inhibitor Response: A Proteomic Analysis
Federico Fusco, Johannes Weigel, Marius Schliemann, et al.
Oncotarget
|
June 10, 2016
Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo
Franziska Blaeschke, Uwe Thiel, Andreas Kirschner, et al.
Science Translational Medicine
|
July 5, 2013
TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer
Magdalena Nauerth, Bianca Weißbrich, Robert Knall, et al.
Blood
|
July 10, 2025
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens
Leonie Rieger, Kilian Irlinger, Franziska Füchsl, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Deutsches Arzteblatt International
|
August 28, 2019
The Systemic Treatment of Melanoma
Patrick Terheyden, Angela Krackhardt, Thomas Eigentler
Deutsche Medizinische Wochenschrift (1946)
|
July 14, 2018
[Immuno-Oncology: A Brief Overview]
Sebastian Kobold, Angela Krackhardt, Hans Schlösser, et al.
Melanoma Research
|
March 3, 2023
The influence of metastatic patterns and tumor load on therapeutic efficacy of immunotherapy in patients with metastatic melanoma as determined by quantitative PET-parameters using [ 18 F]-fluorodeoxyglucose PET/computed tomography
Cornelius Berberich, Mona Mustafa, Yize Zhuwu, et al.
Molecular Therapy Oncolytics
|
January 22, 2019
Enhanced Safety and Efficacy of Oncolytic VSV Therapy by Combination with T Cell Receptor Transgenic T Cells as Carriers
Michael Karl Melzer, Lisa Zeitlinger, Sabine Mall, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 16, 2021
Encorafenib, binimetinib plus pembrolizumab triplet therapy in patients with advanced BRAF<sup>V600</sup> mutant melanoma: safety and tolerability results from the phase I IMMU-TARGET trial
Lisa Zimmer, Elisabeth Livingstone, Angela Krackhardt, et al.
Plos One
|
October 1, 2019
Targeted in-vitro-stimulation reveals highly proliferative multi-virus-specific human central memory T cells as candidates for prophylactic T cell therapy
Benjamin Faist, Fabian Schlott, Christian Stemberger, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
March 26, 2026
SH2D1A/SAP Reflects Immune Activation in Melanoma and Is a Superior Predictive Biomarker of Immune Checkpoint Inhibitor Response: A Proteomic Analysis
Federico Fusco, Johannes Weigel, Marius Schliemann, et al.
Oncotarget
|
June 10, 2016
Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo
Franziska Blaeschke, Uwe Thiel, Andreas Kirschner, et al.
Science Translational Medicine
|
July 5, 2013
TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer
Magdalena Nauerth, Bianca Weißbrich, Robert Knall, et al.
Blood
|
July 10, 2025
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens
Leonie Rieger, Kilian Irlinger, Franziska Füchsl, et al.
Page
of 2